文献速递复苏、休克与脓毒症心脑血管急症

难治性心室颤动的除颤策略

Defibrillation Strategies for Refractory Ventricular Fibrillation.
PubMed 文献 · N Engl J Med · 2022-11-06
一句话结论院外心脏骤停难治性室颤患者中,双序贯体外除颤(DSED)或向量改变(VC)除颤较标准除颤提高出院生存率。

该研究为在加拿大6个急救服务区域开展的整群随机交叉试验,纳入405例院外心脏骤停的成年难治性室颤患者,按急救服务随机分配的策略接受标准除颤、VC除颤或DSED。主要终点出院生存率:DSED组30.4% vs 标准组13.3%(RR 2.21,95%CI 1.33–3.67),VC组21.7% vs 标准组13.3%(RR 1.71,95%CI 1.01–2.88)。DSED组良好神经功能结局比例高于标准组(RR 2.21,95%CI 1.26–3.88),VC组与标准组无显著差异(RR 1.48,95%CI 0.81–2.71)。因COVID-19疫情,数据与安全监察委员会在纳入405例后终止试验。

要点

  • 难治性室颤患者出院生存率:DSED组30.4% vs 标准组13.3%(RR 2.21,95%CI 1.33–3.67)。
  • VC除颤组出院生存率21.7% vs 标准组13.3%(RR 1.71,95%CI 1.01–2.88)。
  • 良好神经功能结局(mRS≤2):DSED组RR 2.21(95%CI 1.26–3.88)高于标准组;VC组RR 1.48(95%CI 0.81–2.71),未达统计学显著。
  • 试验因COVID-19疫情在纳入405例后被数据与安全监察委员会终止。
  • 研究对象为院外心脏骤停的成年难治性室颤患者,策略按急救服务整群随机分配。

适用人群与场景

  • 院外心脏骤停的成年难治性室颤患者。
  • 由加拿大6个急救服务区域的急救人员实施救治。

处置流程与药物剂量

  • DSED:由两台除颤器快速序贯放电。
  • VC除颤:将除颤电极板切换至前后位。
  • 标准除颤作为对照策略。
  • 三种策略按随机分配至急救服务的方案实施。

研究设计与关键结果

  • 研究类型:整群随机交叉试验,在加拿大6个急救服务区域开展。
  • 样本量:共纳入405例患者;标准除颤组136例(33.6%),VC除颤组144例(35.6%),DSED组125例(30.9%)。
  • 主要终点出院生存率:DSED组30.4% vs 标准组13.3%(RR 2.21,95%CI 1.33–3.67);VC组21.7% vs 标准组13.3%(RR 1.71,95%CI 1.01–2.88)。
  • 良好神经功能结局(出院时mRS≤2):DSED组 vs 标准组RR 2.21(95%CI 1.26–3.88);VC组 vs 标准组RR 1.48(95%CI 0.81–2.71)。
  • 次要终点包括室颤终止和自主循环恢复。
  • 试验因COVID-19疫情在纳入405例后被数据与安全监察委员会终止。

证据类型、等级与局限

  • 证据类型:整群随机交叉试验。
  • 资助:加拿大心脏与卒中基金会(Heart and Stroke Foundation of Canada)。
  • 临床试验注册号:DOSE VF,ClinicalTrials.gov NCT04080986。
  • 局限:试验因COVID-19疫情在纳入405例后被数据与安全监察委员会终止。

对床旁实践的改变

  • 对于院外心脏骤停的成年难治性室颤患者,DSED或VC除颤策略较标准除颤提高出院生存率。
  • DSED与更高的良好神经功能结局比例相关;VC除颤与标准除颤相比良好神经功能结局未达统计学显著。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Despite advances in defibrillation technology, shock-refractory ventricular fibrillation remains common during out-of-hospital cardiac arrest. Double sequential external defibrillation (DSED; rapid sequential shocks from two defibrillators) and vector-change (VC) defibrillation (switching defibrillation pads to an anterior-posterior position) have been proposed as defibrillation strategies to improve outcomes in patients with refractory ventricular fibrillation.

METHODS: We conducted a cluster-randomized trial with crossover among six Canadian paramedic services to evaluate DSED and VC defibrillation as compared with standard defibrillation in adult patients with refractory ventricular fibrillation during out-of-hospital cardiac arrest. Patients were treated with one of these three techniques according to the strategy that was randomly assigned to the paramedic service. The primary outcome was survival to hospital discharge. Secondary outcomes included termination of ventricular fibrillation, return of spontaneous circulation, and a good neurologic outcome, defined as a modified Rankin scale score of 2 or lower (indicating no symptoms to slight disability) at hospital discharge.

RESULTS: A total of 405 patients were enrolled before the data and safety monitoring board stopped the trial because of the coronavirus disease 2019 pandemic. A total of 136 patients (33.6%) were assigned to receive standard defibrillation, 144 (35.6%) to receive VC defibrillation, and 125 (30.9%) to receive DSED. Survival to hospital discharge was more common in the DSED group than in the standard group (30.4% vs. 13.3%; relative risk, 2.21; 95% confidence interval [CI], 1.33 to 3.67) and more common in the VC group than in the standard group (21.7% vs. 13.3%; relative risk, 1.71; 95% CI, 1.01 to 2.88). DSED but not VC defibrillation was associated with a higher percentage of patients having a good neurologic outcome than standard defibrillation (relative risk, 2.21 [95% CI, 1.26 to 3.88] and 1.48 [95% CI, 0.81 to 2.71], respectively).

CONCLUSIONS: Among patients with refractory ventricular fibrillation, survival to hospital discharge occurred more frequently among those who received DSED or VC defibrillation than among those who received standard defibrillation. (Funded by the Heart and Stroke Foundation of Canada; DOSE VF ClinicalTrials.gov number, NCT04080986.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Cheskes S, Verbeek PR, Drennan IR, et al. Defibrillation Strategies for Refractory Ventricular Fibrillation. N Engl J Med. 2022. PMID: 36342151. doi:10.1056/NEJMoa2207304

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。